NADAC acquisition cost data for PROCTOFOAM-HC 1%-1% FOAM. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
| 00037682210 | $15.78 | 2022-03-15 | Rx |
Generic: Hydrocortisone/Pramoxine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.3M | 11,712 | 7,245 | $15.00 |
| 2020 | $1.6M | 7,921 | 5,335 | $15.42 |
| 2021 | $2.1M | 9,960 | 6,177 | $16.23 |
| 2022 | $1.9M | 8,947 | 5,813 | $16.76 |
| 2023 | $2.5M | 10,812 | 6,723 | $18.16 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.